Neuroinflammation in FTLD

Inclusion Criteria: * Ability to undergo MRI scanning * For probable FTLD-tau: a clinical diagnosis of PSP, CBS or nfvPPA, or any clinical FTLD spectrum diagnosis with a proven MAPT mutation * For probable FTLD-TDP: a clinical diagnosis of svPPA or any clinical FTLD spectrum diagnosis with a proven GRN mutation or C9orf72 repeat expansion * For presymptomatic mutation carriers: a MAPT mutation, GRN mutation or a C9orf72 mutation without clinical sign of a FTLD spectrum phenotype (CDR 0) For control subjects: no known neurological or psychiatric disorder * For controls: no known neurological or psychiatric disorder Exclusion Criteria: * Other neurological or psychiatric disorder that may affect cognitive functions, such as a brain tumour, multiple sclerosis or drug or alcohol abuse or use of psycho-active medications * CSF profile (β-amyloid, p-tau, t-tau) suggestive of AD pathology * Clinical dementia Rating Scale (CDR) score \>1 * Contra-indication to undergo MRI * Contra-indication to undergo lumbar puncture